Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis
- PMID: 39164549
- DOI: 10.1007/s11686-024-00903-1
Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis
Abstract
Visceral Leishmaniasis is a serious public health problem caused by Leishmania species parasites. Approximately 500 thousand people get Visceral Leishmaniasis (VL) every year. An effective and reliable vaccine against the disease has still not been formulated. Choosing the right adjuvant is important to increase immunogenicity in vaccines prepared with total antigens. In this study, we investigate the ideal adjuvant for use in vaccine formulations against VL. For this purpose, Leishmania antigens (FTLA) obtained from L. infantum parasites by the freeze-thaw method and three different adjuvants (alum-saponin and calcium phosphate) were used. The effectiveness of the formulations was investigated in vitro by cell viability analysis and determination of nitric oxide and cytokine production abilities in J774 macrophage cells. According to the study results, it was determined that formulations prepared with calcium phosphate produced 72% more NO and approximately 7.2 times more IL-12 cytokine. The results obtained showed that calcium phosphate salts can be used as ideal adjuvants in vaccine research against leishmaniasis.
Keywords: Adjuvant; Calcium phosphate; Leishmaniasis; Vaccine.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.Parasitol Int. 2015 Feb;64(1):70-8. doi: 10.1016/j.parint.2014.10.003. Epub 2014 Oct 12. Parasitol Int. 2015. PMID: 25316605
-
Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.Immunobiology. 2015 Sep;220(9):1031-8. doi: 10.1016/j.imbio.2015.05.014. Epub 2015 May 11. Immunobiology. 2015. PMID: 26001730
-
Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.Med Microbiol Immunol. 2015 Aug;204(4):539-50. doi: 10.1007/s00430-014-0367-9. Epub 2014 Nov 29. Med Microbiol Immunol. 2015. PMID: 25432859
-
Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.Curr Opin Microbiol. 2012 Aug;15(4):476-85. doi: 10.1016/j.mib.2012.05.002. Epub 2012 Jun 13. Curr Opin Microbiol. 2012. PMID: 22698479 Review.
-
DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Parasite Immunol. 2016 May;38(5):273-81. doi: 10.1111/pim.12315. Parasite Immunol. 2016. PMID: 27009772 Review.
References
-
- Allahverdiyev A, Bağirova M, Oztel ON, Elçıçek S, Ateş SC, Karaca TD (2010) Approaches and problems in vaccine development against leishmaniasis. Turkiye Parazitolojii Dergisi 34(2):122–130 - PubMed
-
- Kelleci K (2022) Determination of Immunostimulatory Efficacy of Benzimidazole Derivatives Against Leishmania infantum. Sys Rev Pharm 2022; 13(12): 826–830
-
- Severino P, Santana W, Lisboa ES, Santos VLD, Lima ETDS, Cardoso JC, Jain S (2022) Cutaneous/Mucocutaneous Leishmaniasis Treatment for Wound Healing: classical versus New Treatment approaches. Microbiol Res 13(4):836–852 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources